

CTI BIOPHARMA CORP  
Form 4  
June 06, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Plunkett Matthew

(Last) (First) (Middle)

3101 WESTERN AVENUE, SUITE 600

(Street)

SEATTLE, WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
CTI BIOPHARMA CORP [CTIC]

3. Date of Earliest Transaction (Month/Day/Year)  
06/04/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_ Other (specify below)  
EVP, Corporate Development

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	06/04/2014		S <sup>(1)</sup>	700 D	\$ 2.97	608,204	D
Common Stock	06/04/2014		S <sup>(1)</sup>	300 D	\$ 2.975	607,904	D
Common Stock	06/04/2014		S <sup>(1)</sup>	11 D	\$ 3	607,893	D
Common Stock	06/04/2014		S <sup>(1)</sup>	900 D	\$ 3.005	606,993	D
Common Stock	06/04/2014		S <sup>(1)</sup>	2,100 D	\$ 3.01	604,893	D

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	06/04/2014	S <sup>(1)</sup>	1,200	D	\$ 3.015	603,693	D
Common Stock	06/04/2014	S <sup>(1)</sup>	2,300	D	\$ 3.02	601,393	D
Common Stock	06/04/2014	S <sup>(1)</sup>	300	D	\$ 3.025	601,093	D
Common Stock	06/04/2014	S <sup>(1)</sup>	700	D	\$ 3.03	600,393	D
Common Stock	06/04/2014	S <sup>(1)</sup>	100	D	\$ 3.035	600,293	D
Common Stock	06/04/2014	S <sup>(1)</sup>	1,189	D	\$ 3.04	599,104	D
Common Stock	06/04/2014	S <sup>(1)</sup>	800	D	\$ 3.045	598,304	D
Common Stock	06/04/2014	S <sup>(1)</sup>	700	D	\$ 3.05	597,604	D
Common Stock	06/04/2014	S <sup>(1)</sup>	500	D	\$ 3.06	597,104	D
Common Stock	06/04/2014	S <sup>(1)</sup>	200	D	\$ 3.07	596,904	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 6)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V (A) (D)		

